Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea
Moderna Fully Enrolls COVE Trial
Executive Summary
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
You may also be interested in...
Coronavirus Update: Pfizer, BioNTech Hit Ground Running On Vaccine EUA
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains
The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.
'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains
The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.
Need a specific report? 1000+ reports available
Buy Reports